Health & Environmental Research Online (HERO)


Print Feedback Export to File
7413188 
Journal Article 
Adjuvant Systemic Therapy in Breast Cancer 
Goldfarb, S; Zhi, WI; , 
2019 
Springer International Publishing 
Cham 
Oncoplastic and Reconstructive Breast Surgery 
179-194 
Patients with early-stage breast cancer are treated with curative intent. The goal of adjuvant therapy is to improve overall survival [1, 2]. After surgery, although there is no evidence of gross remaining disease, patients still have a risk of relapse from occult micrometastatic disease. The goal of adjuvant systemic therapy is to decrease risk of recurrence while minimizing toxicities and overtreatment. Therefore, it is important to identify patient populations that will benefit most from treatment in order to avoid unnecessary toxicities [3–5]. Patients require different adjuvant therapies based on their risk of recurrence, stage of disease, and tumor biology. In this chapter, we will discuss systemic adjuvant therapy including endocrine therapy, chemotherapy, and HER2-targeted therapy [6, 7].